SEARCH

SEARCH BY CITATION

Keywords:

  • parathyroid cells;
  • parathyroid cancer;
  • parathyroid hormone;
  • genetic research;
  • genotype-phenotype correlation

Abstract

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

Telomerase activity has been correlated to parathyroid carcinoma. Because its role in acquisition of a malignant phenotype by parathyroid cells is unclear, we treated telomerase-positive cultured human parathyroid cancer cells with the telomerase inhibitor AZT, evaluating cell telomerase activity, cytotoxic effects, growth, and morphological changes. In vitro exposure of these cells to AZT correlated with inhibition of cell proliferation.

Introduction: Parathyroid carcinoma represents an uncommon cause of primary hyperparathyroidism, whose spectrum of clinical presentation, degree of malignancy, and prognosis are difficult to be properly identified. Neck surgery, specifically an en bloc resection of primary tumor, is the only curative treatment. Alternatively, affected patients could undergo repetitive palliative surgical exeresis of metastatic nodules. It has been previously shown that telomerase activity is specifically present in parathyroid carcinoma cells, being absent in hyperplastic and adenomatous tissues. Thus, determination of telomerase activity could represent either a useful diagnostic molecular marker for human parathyroid carcinoma or a potential target for pharmacological intervention in a malignant neoplasia usually resistant to chemo- and radiotherapeutic interventions.

Materials and Methods: To further investigate the role of telomerase activity in acquisition of a malignant phenotype by parathyroid cells, we treated telomeric repeat amplification protocol-positive cultured human parathyroid cells with the telomerase inhibitor zidovudine, 3′-azido-3′deoxythymidine (AZT), evaluating cell telomerase activity, growth characteristics, potential cytotoxic effects, and morphological changes.

Results: Our findings indicate that in vitro exposure of human parathyroid cancer cells to AZT resulted in intracellular accumulation of AZT-monophosphate (AZT-MP) and inhibition of telomerase, which correlate with inhibition of human parathyroid cancer cell proliferation. Moreover, we also found that AZT induced an apoptotic rather than a necrotic type of cellular death. None of these effects were observed in human adenomatous parathyroid cells in culture.

Conclusions: Altogether these results indicate that AZT may be a highly effective agent against cancer parathyroid cells proliferation, which is an extremely important observation for a neoplasia which shows lack of response to classical pharmacological and physical antiblastic treatments.


INTRODUCTION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

ZIDOVUDINE, 3′-AZIDO-3′DEOXYTHYMIDINE (AZT),(1) is a chemotherapic molecule commonly used as antiviral agent, alone or in combination with other drugs, in the therapy of AIDS and human T-cell lymphotropic virus type I (HTLV)-I-associated adult T-cell leukemia/lymphoma.(2) Moreover, phase I and II clinical trials in gastrointestinal cancers showed that AZT contributed to regression of some tumors.(3–8)

AZT is a thymidine analog phosphorylated at the intracellular level to AZT-triphosphate (AZT-TP) by thymidine kinase enzyme, and in this form, it can be incorporated into viral DNA, acting as a false substitute for the viral RT, blocking chain elongation,(9) preferentially at the telomeric ends of chromosomes in cancer cells.(10) In combination with interferon-α, AZT is able to induce apoptosis in herpes virus-associated lymphomas,(11) and alone or in combination with other antimetabolites, it inhibits growth of human bladder, colon, and mammary cancer cells.(12,13)

Parathyroid carcinoma is an uncommon cause of primary hyperparathyroidism, and its spectrum of clinical presentation, degree of malignancy, and prognosis are difficult to identify.(14,15) An en bloc resection of the primary tumor is considered the only curative treatment. Alternatively, affected patients can undergo repetitive palliative surgical exeresis of metastatic nodules.

In a previous paper, we showed that telomerase activity, evaluated by telomeric repeat amplification protocol, is specifically present in parathyroid carcinoma cells compared with benign forms of parathyroid neoplasia.(16) Lack of telomerase activity in hyperplastic and adenomatous tissues was successively confirmed by others.(17–19) Thus, the determination of telomerase activity could represent either a useful diagnostic molecular marker for human parathyroid carcinoma or a potential target for pharmacological intervention in a malignant neoplasia usually resistant to chemo- and radiotherapeutic interventions.

To test this hypothesis, we decided to investigate the phenotype of telomeric repeat amplification protocol-positive cultured human parathyroid cancer (HPC) cells treated with the telomerase inhibitor, AZT, evaluating telomerase activity, growth characteristics, potential cytotoxic effects, and morphological changes.

MATERIALS AND METHODS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

Primary cultures of human parathyroid cells

Human parathyroid malignant tissue was removed from two patients (a 72-year-old male [preparation I] and a 65-year-old female [preparation II]) who underwent surgery for metastatic parathyroid carcinoma. Histopathological features, such as nuclear atypia, numerous cells in mitosis, fibrous bands, and microvascular or capsular invasion were present. Parathyroid adenomatous tissue was obtained from three patients affected by benign primary hyperparathyroidism (a 66-year-old male [preparation III] and two female patients [preparations IV and V], who were 70 and 72 years old, respectively). Tumor samples were obtained in accordance with a protocol approved by the institutional review board for human studies; patients provided informed consent as dictated by this protocol. Cells were used within the first 10 days of primary culture, when >90% of the cell population showed immunostaining for parathyroid hormone (PTH).(20)

A fragment of the parathyroid pathological tissue was collected in sterile conditions and transported to the laboratory. Tissue was minced into small fragments and digested at 37°C for 2 h with 1.2 mg/ml collagenase type II (Sigma, Milan, Italy) in a mixture (1:1) of DMEM:Ham'sF-12 medium (DMEM:F-12 medium; Sigma). Digested tissue fragments were mechanically dispersed by aspiration into a pipette in DMEM:F-12 medium and successively centrifuged at 500g. The pellet was resuspended in DMEM:F-12 medium supplemented with 5% calf serum, 1% Nutridoma (Sigma), 1 mM CaCl2, 0.5 mM MgCl2, and antibiotics (growth medium). Cell suspension was filtered through 60 and 150 mesh screens (wire diameter, 0.191 and 0.066 mm, respectively; Sigma). The cells collected out of the 150 filters were distributed in plastic culture dishes in growth medium at a density of 5 × 105 cells/100-mm dish and cultured at 37°C in humidified 95% air/5% CO2 atmosphere.

Measurement of telomerase activity

Telomerase activity in intact cells was measured using a modified nonradioactive telomeric repeat amplification protocol and corrected for cell number.(21,22) Telomere length was measured by a solution hybridization-based method.(22) In brief, genomic DNA was isolated, and 10 μg of DNA was digested at 37°C overnight with 10 units each of HinfI/CpoI/HeaIII. The probe (TTAGGG)4 was labeled with γ-[32P]ATP with polynucleotide T4 kinase. Three nanograms of the probe was added to 2.5 μg of DNA solution. After denaturation at 98°C for 5 minutes, hybridization was performed at 55°C overnight. The resulting samples were electrophoresed on a 0.7% agarose gel. After drying under a vacuum without heating, the gel was exposed to a phosphorimage screen, and the results were analyzed using the area under the curve method by the ImageQuant software. The point representing 50% of the area under the curve was the mean telomere length. Genomic DNA was extracted from homogenated human parathyroid cultured cells after different times of exposure to AZT. Human malignant mammary cancer (MCF-7) cells (catalog no. HTB-22; ATCC) were used as a positive control.(23,24) HPC cells were treated with 100 μM AZT for different times, and total cells were collected and analyzed for the mean telomere length. All the experiments were carried out in triplicate.

Human parathyroid cells were also evaluated for mutations of the TP53 gene in exons 5–8. SSCP-screening kit by ANALITICA (Padova, Italy) was used to detect the presence of any kind of mutation in exons 5, 6, 7, and 8 of the TP53 gene, according to the manufacturer's instructions.

Morphological studies

To examine both density and morphological features, HPC cells cultured in growth medium with and without 100 μM AZT for 72 h were observed under phase contrast light microscopy.

For light microscopy analysis, HPC cells were cultured on glass slides in the presence or in the absence of 100 μM AZT. Briefly, HPC cells cultured on glass slides were fixed in formaldehyde/glyceraldehyde (1:1) buffer for 3 minutes and washed twice in PBS.

For transmission electron microscopy (TEM) analysis, human parathyroid cells were cultured in growth medium with and without 100 μM AZT for 72 h, and the cells were collected by gentle scraping and centrifuged at 500g. The cell pellet was fixed in 4% cold glutaraldehyde in 0.1 M cacodylate buffer and postfixed in 1% osmium tetroxide in 0.1 M PBS at room temperature. The pellet was dehydrated in a graded acetone series, passed through propylene oxide, and embedded in epon 812. Ultrathin sections were cut, using a diamond knife, with a Leica Ultracut R microtome, mounted on formvar-coated Cu/Rh grids, stained with uranyl acetate and lead citrate, and observed with a Philips 410 LS transmission electron microscope.

Cell growth and viability

HPC cell proliferation was evaluated by [3H]thymidine uptake as previously described.(16) Briefly, HPC cells were incubated for 48 h under the indicated experimental conditions. In the last 6 h, [3H]thymidine was added, and cell mitogenesis was evaluated by the uptake of the labeled nucleotide.

Cell growth was measured by cell counting by plating HPC cells at a density of 3 × 105 cells/35-mm well under the indicated experimental conditions. After 96 h, HPC cells were detached with a trypsin solution (0.25% in PBS), and cell number was evaluated by a hemocytometer.

Cell viability was assessed by trypan blue dye uptake/exclusion assay. One drop of cell suspension was added to one drop of trypan blue dye solution (0.3% in PBS), and stained versus unstained cells were counted and expressed as percentage. Results were expressed as mean ± SD of triplicate experiments.

Flow cytometry

Antibody staining was performed on 1,000,000 cells for the conjugated primary antibody. Apoptosis was assayed with propidium iodide/annexin V staining. For propidium iodide/annexin V-FITC staining of apoptosis, cells were washed with annexin V FACS buffer (HBSS buffer with calcium, magnesium, sodium azide, and 0.5% BSA), incubated on ice with a 1:30 dilution of annexin V-FITC (Caltaq Laboratories, Burlingame, CA, USA) for 30 minutes, and washed in FACS buffer. Before FACS analysis, propidium iodide at 5 μg/ml (Sigma) was added to the cells and gently mixed. Stained cells were immediately analyzed by FACS.

PTH release

HPC cells were plated at a density of 1 × 106 cells/35-mm dishes in growth medium for 24 h. Cells were exposed to DMEM/F-12 medium containing 0.01, 0.1, and 1.0 mM AZT for 6 h of incubation, media were collected and centrifuged at 2000g, and supernatants were frozen at −80°C. Intact human PTH (iPTH) released into the medium was evaluated by a commercially available IRMA kit for intact human PTH (Technogenetics, Milan, Italy). All experiments were carried out in triplicate and expressed as mean ± SD.

In vitro drug activity evaluation

Drug treatment was initiated after cells were allowed to attach to the growth surface. AZT (Sigma) is converted intracellularly to AZT-TP, which inhibits telomerase. Hence, we examined the effect of AZT only in intact cells. AZT effects measured at the indicated times at concentrations ranging from 0.1 μM to 1 mM were modifications of (1) morphological appearance of HPC cells both under optic and TE microscopy; (2) cell viability; (3) cell proliferative properties; (4) cell apoptosis; (5) iPTH release; and (6) telomerase activity. All experiments were carried out in triplicate and expressed as mean ± SD.

AZT phosphorylation assay

Intracellular levels of phosphorylated AZT were measured using published methods.(25) Cells were plated in 24-well plates at 5 × 105 cells/well and incubated with 5 μg/ml [3H]AZT (Sigma). After 24 h of incubation, cells were harvested and washed with PBS twice. Cell pellets were extracted with cold 65% methanol on ice for 30 minutes and spun at 1500 rpm for 5 minutes. The supernatants were collected and applied to HPLC for measurements of AZT-monophosphate (AZT-MP), because cytotoxicity of AZT correlates with AZT-MP levels, whereas anti-human immunodeficiency virus activity correlates with AZT-TP levels.(26,27)

Statistical evaluation

Data were expressed as mean ± SD of triplicate experimental points. Statistical differences were analyzed using one-way ANOVA, and significance was evaluated by standard χ2 test using Statistica 5.1 (Statsoft, Tulsa, OK, USA).

RESULTS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

Telomere length

The two HPC cell preparations showed comparable baseline telomere length (preparation I: 1675 ± 210 bp; preparation II: 2016 ± 307 bp). MCF-7 cells showed a telomere length of 2680 ± 218 bp. The three parathyroid adenomas resulted negative for telomerase activity (preparations III-V). None of the five samples (I-V) showed mutations in exons 5–8 of the TP53 gene.

Figure 1 shows the time-dependent telomerase inhibition by 0.1 mM AZT in HPC cells with significant effect after a 48-h incubation (preparations I and II). Results were corrected per cell number and expressed as mean ± SD of three different experiments.

thumbnail image

Figure Fig. 1.. Alteration of telomerase activity in HPC cells (preparation I, •; preparation II, ○] after 100 μM AZT treatment. Telomerase activity in total cells was detected by telomeric repeat amplification protocol and corrected for cell number. Data are mean ± SD of three experiments. *p < 0.05 and **p < 0.01 compared with untreated controls at time 0.

Download figure to PowerPoint

Changes in functional and morphological features of HPC cells after AZT treatment

According to the trypan blue dye uptake/exclusion analysis, no cytotoxic effect was observed in cell preparations I and II at any of the AZT tested concentrations (data not shown).

Similarly, no significative changes in iPTH release were observed in untreated (preparation I: 100 ± 21 pg/106 cells; preparation II: 80 ± 18 pg/106 cells) and 0.1 mM AZT-treated HPC cells after a 6-h incubation (preparation I: 110 ± 17 pg/106 cells; preparation II: 85 ± 8 pg/106 cells). Lower (0.01 mM) and higher (1 mM) doses of AZT were similarly inert on iPTH release by HTC cells (data not shown).

Figures 2A and 2B compare the phase contrast morphology of HPC cells after 72-h exposure to 100 μM AZT. Treatment with AZT produced a change of the polygonal cell morphology of HPC cells into a spindle-shaped cellular profile. Moreover, the same treatment resulted in a reduction of cell number, with cells growing as sparse elements, as confirmed by cell counting of selected fields (preparation I: 65 ± 8% reduction versus control, p < 0.05; preparation II: 58 ± 4% reduction versus control, p < 0.01). Conversely, 0.01-1 mM AZT did not modify the phenotypic appearance of the telomerase-negative parathyroid adenomatous cells in preparations III-V (Figs. 2C and 2D).

thumbnail image

Figure Fig. 2.. Contrast phase morphology of HPC cells (preparation I) cultured in the (A) absence or (B) presence of 100 μM AZT for 72 h. Treatment with AZT produced a change of the polygonal cell morphology into spindle-shaped cells, with reduction of cell number. (C and D) AZT-untreated and -treated parathyroid adenoma cells, respectively (original magnification, ×100). Similar results were obtained in preparation II.

Download figure to PowerPoint

Ultrastructurally, HPC cells were characterized by round to oval shape and irregular profile because of the presence of numerous interdigitating projections of the cell surface. The nucleus was round, centrally located, and contained moderately clumped and marginated chromatin and inconspicuous nucleoli. According to the cell cytoplasm content, it was possible to distinguish a spectrum of cell types, as seen in most parathyroid neoplasms. In untreated HPC cells cultures, cells presented features of the so-called “chief cells,” “inactive chief cells,” and “oxyphil cells.” Chief cells contained a well-developed Golgi apparatus, stacks of rough endoplasmic reticulum (RER) cisternae, elongated mitochondria, abundant glycogen particles, and several round to oblong electron dense endosecretory granules measuring 100–250 nm (Fig. 3A). Inactive chief cells were readily recognized by the presence of abundant cytoplasmic glycogen particles and more inconspicuous organelles and endosecretory granules (Fig. 3B). HPC cells treated with 100 μM AZT showed prevalent features of oxyphil cells, which were characterized by the presence of numerous mitochondria, a moderately developed secretory apparatus, and rare endosecretory granules (Fig. 3C). Transitional chief/oxyphil cells were also present, sharing ultrastructural features of both cell types (i.e., numerous mitochondria, a well-developed secretory apparatus, and numerous endosecretory granules). Such findings have been confirmed by light microscopy using randomized cell counting, with a significant increase of transitional or oxyphil cells compared with untreated HPC cells (preparation I: 63 ± 6% versus 19 ± 4%; p < 0.05; preparation II: 78 ± 6% versus 11 ± 7%, p < 0.01). Finally, HPC cells treated with 0.1 and 1.0 mM AZT presented a typical apoptotic morphology, with reduced cell volume, condensation of chromatin, and fragmentation of the nucleus. Typical apoptotic bodies were also observed (Fig. 3D). Similar observations were obtained in the two HPC cell preparations (I and II). Conversely, in the same experimental conditions, 100 μM AZT did not seem to induce any significant modifications in cells obtained from human adenomatous tissues (preparations III-V; Fig. 3D1).

thumbnail image

Figure Fig. 3.. Ultrastructural features of cultured HPC cells. (A) Untreated HPC cell cultures, with cells presenting the ultrastructural appearance of chief cells. They show several mitochondria, abundant glycogen particles, and several round electron dense endosecretory granules. (B) Untreated HPC cell cultures showing features of inactive chief cells, with abundant cytoplasmic glycogen particles in the peripheral cytoplasm and more inconspicuous organelles and endosecretory granules mainly aggregated near the nucleus. (C) HPC cells treated for 72 h with 100 μM AZT show features of oxyphil cells, with cytoplasm containing numerous mitochondria and a moderately developed secretory apparatus. (D) Apoptotic body seen in a 100 μM AZT-treated HPC cell cultures. (D1) Parathyroid adenoma cells treated with 100 μM AZT. Original magnification, (A) ×7100 and (B-D) ×4400.

Download figure to PowerPoint

Inhibition of HPC cell mitotic activity and proliferation by AZT

Mitotic activity of HPC cells was evaluated by [3H]thymidine uptake. AZT in a dose range from 0.1 μM to 1.0 mM inhibited [3H]thymidine uptake in a dose-dependent fashion (Fig. 4). No effects of AZT on DNA synthesis were observed on adenomatous human parathyroid cells (preparations III and IV; Fig. 4).

thumbnail image

Figure Fig. 4.. Effect of AZT on [3H]thymidine uptake in parathyroid cells in primary cultures. AZT was used at concentrations from 0.1 μM to 1.0 mM. Parathyroid cells were incubated for 48 h with various AZT doses, and in the last 6 h of incubation, [3H]thymidine was added to evaluate the uptake of the labeled nucleotide. Results are expressed as mean ± SD of three experimental points. *p < 0.05; **p < 0.01.

Download figure to PowerPoint

The effect of AZT on DNA synthesis was confirmed by the evaluation of HPC cell proliferation measured by cell counting. Human parathyroid cultured cells were incubated for 96 h with AZT in a range of concentrations from 0.1 μM to 1.0 mM. A dose-dependent inhibition of cell growth was observed in the two HPC cell preparations (I and II) from a concentration of 10 mM AZT, whereas no effect was evident on preparation III of human parathyroid adenomatous cells (Fig. 5).

thumbnail image

Figure Fig. 5.. Effect of AZT on parathyroid cell proliferation. AZT was used at concentrations from 0.1 μM to 1.0 mM. Parathyroid cells were incubated for 96 h with various AZT doses and then detached by trypsin solution to count cell number by a hemocytometer (preparation I, •; preparation II, ○; preparation III, □). Experiments were carried out in triplicate, and results are expressed as percentage ± SD vs. control. *p < 0.05; **p < 0.01.

Download figure to PowerPoint

In vitro induction of apoptosis in HPC cells by AZT treatment

HPC cells (preparations I and II) were cultured for 48 h in 0.1 μM to 1 mM AZT concentrations, and apoptosis was measured by annexin V flow cytometry. AZT induced apoptosis in a dose-dependent manner in both HPC cell preparations (Fig. 6). AZT did not increase apoptosis in human parathyroid adenomatous cells (preparations III-V; data not shown).

thumbnail image

Figure Fig. 6.. AZT-induced apoptosis in HPC cell preparations I and II. Cells were treated for 48 h with 0.1 μM to 1.0 mM doses of AZT and analyzed for apoptosis by propidium iodide/annexin flow cytometry. The data are the mean ± SD of results obtained from three independent experiments.*p < 0.01.

Download figure to PowerPoint

Intracellular AZT-MP levels correlate with sensitivity to AZT-mediated apoptosis and growth arrest

In AZT-sensitive HPC cells (preparations I and II), a markedly higher level of AZT-MP was detected than in resistant cell preparations (III-V; Fig. 7). This suggests that AZT-MP may preferentially accumulate in HPC cells sensitive to AZT-mediated apoptosis and growth arrest.

thumbnail image

Figure Fig. 7.. Intracellular AZT-MP levels. AZT-sensitive cell preparations (I and II) and resistant cell preparations (III-V) were cultured in the presence of [3H] AZT for 24 h. Intracellular levels of AZT-MP were determined by HPLC. Data are presented as nanograms of AZT-MP per million cells. Results are expressed as mean ± SD of three different experimental points.

Download figure to PowerPoint

DISCUSSION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

Parathyroid carcinoma represents an uncommon case of primary hyperparathyroidism.(14,15) Unfortunately, this rare disorder does not show any clarity to unequivocally address both clinical and pathological differential diagnosis with parathyroid adenoma or hyperplasia. The optimal treatment consists of an en bloc tumor resection with ipsilateral thyroid lobectomy when the diagnosis is suspected and until it is proven otherwise. Moreover, reoperation in patients with localized parathyroid carcinoma is recommended because it relieves symptoms of hypercalcemia, and it normalizes serum calcium and PTH levels in most patients. Patients who have persistent or recurrent parathyroid carcinoma should have localizing studies to identify loco-regional or distant tumor sites.(28) For patients with unresectable parathyroid carcinoma, a protocol-based treatment with chemotherapy and external radiotherapy should be considered.(29) Unfortunately, late diagnosis at a metastatic stage of this malignancy is not infrequent, and treatment with nonsurgical anticancer therapies is doubtful.(30) For all these reasons, the search for specific molecular markers to improve the precocious diagnosis of parathyroid tumors has had a great impact in the past decade.(31–36)

In a previous study, we observed increased telomerase activity in primary cultures of HPC cells compared with benign parathyroid lesions,(16) as indirectly confirmed by others,(17) suggesting telomerase activity as an additional molecular marker for parathyroid carcinoma diagnosis. Progressive shortening of telomeres constitutes a molecular mechanism by which normal cells avoid uncontrolled proliferation. Telomerase is present in nearly all immortal cell lines, germ-line cells, stem cells, and 90% of human tumors, but seldom in normal somatic cells.(23) Telomerase is a ribonucleic DNA polymerase that synthesizes telomeric repeats de novo and is involved in multiple cellular processes, including cell differentiation, proliferation, inhibition of apoptosis, tumorigenesis, and possibly DNA repair and drug resistance.(37–42) Most human cancers exhibit an upregulated or reactivated telomerase activity.(21) The selective expression of telomerase in tumor cells makes telomerase an attractive therapeutic target.

AZT is a thymidine analog, originally developed as an antineoplastic agent with biologic activity in phase I and II clinical trials in patients with solid tumors.(4–8) Acting as a false substitute for viral reverse transcriptase, AZT has been recently used almost exclusively as an antiretroviral agent.(9,43–45) AZT has multiple pharmacological actions, including inhibition of human telomerase reverse transcriptase component.(46) It has been established that AZT, alone or in combination with other anticancer drugs, is able to decrease the in vitro cell growth of several neoplastic cell lines.(2,3,9–13) This was further confirmed by in vivo clinical data both in primary and metastatic tumors.(2,3,47–54)

In this study, we investigated the possible mechanism of action of AZT by in vitro examination of several HPC cellular parameters, including morphology proliferation, apoptosis, differentiation, telomerase activity, and AZT metabolism. Human parathyroid cells derived from benign lesions served as controls. This study indicates that in vitro exposure of HPC cells to AZT resulted in inhibition of telomerase and intracellular accumulation of AZT-MP. Our data showed a correlation between intracellular levels of the metabolite AZT-MP, telomerase inhibition, and inhibition of HPC cell proliferation. We also found that AZT induced an apoptotic rather than a necrotic type of cellular death, as previously shown in Herpes virus-associated lymphomas.(11) Anticancer agents that induce tumor apoptosis would also likely lessen patient morbidity from complications of tumor lysis. The AZT effect was not observed in telomerase-negative human benign parathyroid cells. Collectively, these results support the hypothesis that targeting of telomerase activity produces antiproliferative effect in telomerase-positive HPC cells.

An interesting and unexpected finding was the AZT-induced morphological changes of HPC cells, which acquire a quiescent and less functioning phenotype, with no acute effects of AZT on PTH release. HPC cells treated with AZT showed features of oxyphil cells, characterized by a moderately developed secretory apparatus and rare endosecretory granules. Additional studies are needed to determine the mechanisms by which AZT induces ultrastructural changes of HPC cells and the potential conditions of this phenomenon with AZT pharmacological actions (i.e., inhibition of reverse transcriptase, human telomerase reverse transcriptase component, integrase, DNA polymerase γ, and thymidine kinase).(44–46)

Although further in vitro and in vivo evidence is needed, these results preliminarily indicate that AZT can be proposed as a potential antiparathyroid cancer agent. The tumor selectivity of this therapeutic approach is suggested by the finding that AZT is inactive in benign human parathyroid hyperfunctioning cells. To confirm these findings, more observations are necessary. However, if these observations are valid, they can be translated into clinical trials that use AZT, alone or in combination with other chemotherapeutic agents. This is extremely needed for a neoplasia that shows lack of response to classical anticancer treatments. Recently, molecules able to mimic the calcium effect, named calcium-mimetics or calcimimetics, activated the calcium-sensing receptor (CaSR) present on the cell surface of parathyroid cells and inhibited parathyroid function. Specifically, class II calcimimetics, NPS R568 and AMG 073 (cinacalcet HCl), have been successfully used in normalizing serum calcium levels in patients with parathyroid carcinoma.(55,56) In these patients, cinacalcet HCl was effective in reducing serum calcium levels, with serum calcium reductions maintained up to 18 months. Thus, cinacalcet HCl could potentially be an effective therapy for the treatment of hypercalcemia in patients with parathyroid carcinoma or recurrent primary HPT after parathyroidectomy (PTX),(56) associated with a subjective improvement in symptoms. Although the effects on tumor burden are still unknown, cinacalcet HCl seems to significantly ameliorate states of severe PTH-dependent hypercalcemia.(57) Undoubtedly, combinations of drugs such as AZT and calcimimetics, respectively acting on inhibition of parathyroid cells proliferation rate and PTH secretion, may offer an important opportunity to reduce the severity of both biological and clinical progression of parathyroid carcinoma.

Acknowledgements

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES

This study was supported by A.I.R.C. 2000 and Fondazione Ente Cassa di Risparmio di Firenze (MLB).

REFERENCES

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. Acknowledgements
  8. REFERENCES
  • 1
    Izuta S, Saneyoshi M, Sakurai T, Suzuki M, Kojima K, Yoshida S 1991 The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms. Biochem Biophys Res Commun 179: 776783.
  • 2
    Bazarbachi A, Nasr R, El-Sabban ME, Mahe A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y, Dianoux L, Chelbi-Alix MK, de The H, Hermine O 2000 Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 14: 716721.
  • 3
    Falcone A, Lencioni M, Brunetti I, Pfanner E, Allegrini G, Antonuzzo A, Andreuccetti M, Malvaldi G, Danesi R, Del Tacca M, Conte PF 1997 Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. Ann Oncol 8: 539545.
  • 4
    Posner MR, Darnowski JW, Calabresi P, Brunetti I, Corvese D, Curt G, Cummings FJ, Clark J, Browne MJ, Beitz J 1990 Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: A phase I study. J Natl Cancer Inst 82: 17101714.
  • 5
    Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, Bigley J, Calabresi P 1992 High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer 70: 29292934.
  • 6
    Beitz JG, Darnowski JW, Cummings FJ, Browne M, Clark J, Bigley J, Weitberg A 1992 A Phase I and pharmacologic analysis of fluorouracil + leucovorin combined with infused high-dose zidovudine. Proc Am Assoc Cancer Res 33: 427.
  • 7
    Posner MR, Darnowski JW, Tessitore J, Bigley J, Parker LM, Stuart K, Huberman MA 1993 Phase I trial of high dose, intravenous zidovudine (AZT) and 5-fluoracil/leucovorin and cisplatin. Proc Am Assoc Cancer Res 12: 162.
  • 8
    Anand A, Ellis M, Tessitore J, Huberman M, Parker LM, Stuart K, Posner MRA 1995 Phase I study of intermittent high-dose zidovudine. 5-fluorouracil leucovirin and cisplatin. Proc Am Assoc Cancer Res 14: 481.
  • 9
    Furman PA, Barry DW 1988 Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med 85: 176181.
  • 10
    Multani AS, Furlong C, Pathak S 1998 Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3′-azido-2′-3′-dideoxythymidine. Int J Oncol 13: 923925.
  • 11
    Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C, Agarwal RP, Xia W, Boise LH, Podack E, Harrington WJ Jr 1999 Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas. Cancer Res 59: 55145520.
  • 12
    Pressacco J, Erlichman C 1993 Combination studies with 3′-azido-3′-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem Pharmacol 46: 19891997.
  • 13
    Melana SM, Holland JF, Pogo BG 1998 Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin Cancer Res 4: 693696.
  • 14
    Wang CA, Gaz RD 1985 Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 149: 522527.
  • 15
    Shane E 2001 Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 86: 485493.
  • 16
    Falchetti A, Becherini L, Martineti V, Morelli A, Benvenuti S, Picariello L, Gennari L, Lampugnani R, Bordi C, Brandi ML 1999 Telomerase repeat amplification protocol (TRAP): A new molecular marker for parathyroid carcinoma. Biochem Biophys Res Commun 265: 252255.
  • 17
    Velin AK, Herder A, Johansson KJ, Trulsson LM, Smeds S 2001 Telomerase is not activated in human hyperplastic and adenomatous parathyroid tissue. Eur J Endocrinol 145: 161164.
  • 18
    Kammori M, Nakamura K, Kanauchi H, Obara T, Kawahara M, Mimura Y, Kaminishi M, Takubo K 2002 Consistent decrease in telomere length in parathyroid tumors but alteration in telomerase activity limited to malignancies: Preliminary report. World J Surg 26: 10831087.
  • 19
    Kammori M, Nakamura K, Ogawa T, Mafune K, Tatutomi Y, Obara T, Onoda N, Fujiwara M, Izumiyama-Shimomura N, Mori M, Kaminishi M, Takubo K 2003 Demonstration of human telomerase reverse transcriptase (hTERT) in human parathyroid tumours by in situ hybridization with a new oligonucleotide probe. Clin Endocrinol (Oxf) 58: 4348.
  • 20
    Brandi ML, Fitzpatrick LA, Coon HG, Aurbach GD 1986 Bovine parathyroid cells: Cultures maintained for more than 140 population doublings. Proc Natl Acad Sci USA 83: 17091713.
  • 21
    Naasani I, Seimiya H, Tsuruo T 1998 Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 249: 391396.
  • 22
    Gan Y, Engelke KJ, Brown CA, Au JLS 2001 Telomere amount and length assay. Pharm Res 18: 16551659.
  • 23
    Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW 1994 Specific association of human telomerase activity with immortal cells and cancer. Science 266: 20112015.
  • 24
    Soule HD, McGrath CM 1986 A simplified method for passage and long-term growth of human mammary epithelial cells. In Vitro Cell Dev Biol 22: 612.
  • 25
    Agarwal RP, Mian AM 1991 Thymidine and zidovudine metabolism in chronically Zidovudine-exposed cells in vitro. Biochem Pharmacol 42: 905911.
  • 26
    Törnevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S 1995 Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas antihuman immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 49: 829837.
  • 27
    Bridges EG, Faraj A, Sommadossi JP 1993 Inhibition of mammalian dna polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine and 3′-amino-3′-deoxythymidine. Biochem Pharmacol 45: 1571.
  • 28
    Dotzenrath C, Goretzki PE, Sarbia M, Cupisti K, Feldkamp J, Roher HD 2001 Parathyroid carcinoma: Problems in diagnosis and the need for radical surgery even in recurrent disease. Eur J Surg Oncol 27: 383389.
  • 29
    Kebebew E 2001 Parathyroid carcinoma. Curr Treat Options Oncol 2: 347354.
  • 30
    Rasmuson T, Kristoffersson A, Boquist L 2000 Positive effect of radiotherapy and surgery on hormonally active pulmonary metastases of primary parathyroid carcinoma. Eur J Endocrinol 143: 749754.
  • 31
    Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL Jr, Benedict WF, Arnold A 1994 Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 330: 757761.
  • 32
    Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A 1994 p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 78: 13201324.
  • 33
    Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV 1996 Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 45: 195200.
  • 34
    Yoshimoto K, Endo H, Tsuyuguchi M, Tanaka C, Kimura T, Iwahana H, Kato G, Sano T, Itakura M 1998 Familial isolated primary hyperparathyroidism with parathyroid carcinomas: Clinical and molecular features. Clin Endocrinol (Oxf) 48: 6772.
  • 35
    Dionisio P, Stramignoni E, Passarino G, Pucci A, Valenti M, Berto IM, Portigliatti Barbos M, Cadario A, Gasparri G, Bajardi P 1996 Recurrent secondary hyperparathyroidism due to parathyroid carcinoma: Usefulness of Ki-67 immunostaining in the diagnosis of a malignant parathyroid tumor. Nephron 74: 720723.
  • 36
    Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A 2003 Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349: 17221729.
  • 37
    Zakian VA 1995 Telomeres: Beginning to understand the end. Science 270: 16011607.
  • 38
    Urquidi V, Tarin D, Goodison S 2000 Role of telomerase in cell senescence and oncogenesis. Annu Rev Med 51: 6579.
  • 39
    Fu W, Begley JG, Killen MW, Mattson MP 1999 Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 274: 72647271.
  • 40
    Nugent CI, Bosco G, Ross LO, Evans SK, Salinger AP, Moore JK, Haber JE, Lundblad V 1998 Telomere maintenance is dependent on activities required for end repair of double-strand breaks. Curr Biol 8: 657660.
  • 41
    Ishikawa T, Kamiyama M, Hisatomi H, Ichikawa Y, Momiyama N, Hamaguchi Y, Hasegawa S, Narita T, Shimada H 1999 Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells. Cancer Lett 141: 187194.
  • 42
    Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL 2003 Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 63: 579585.
  • 43
    Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley RT, Jackson GG, Durack DT, Andrews JC, Nusinoff-Lehrman S, Barry DW, and the AZT Collaborative Working Group 1989 Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA 262: 24052410.
  • 44
    Furman PA, Painter GR, Anderson KS 2000 An analysis of the catalytic cycle of HIV-1 reverse transcriptase: Opportunities for chemotherapeutic intervention based on enzyme inhibition. Curr Pharm Des 6: 547567.
  • 45
    Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, Barry DW 1986 Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 83338337.
  • 46
    Strahl C, Blackburn EH 1996 Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16: 5365.
  • 47
    Murakami J, Nagai N, Shigemasa K, Ohama K 1999 Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer 35: 10271034.
  • 48
    Andreuccetti M, Allegrini G, Antonuzzo A, Malvaldi G, Conte PF, Danesi R, Del Tacca M, Falcone A 1996 Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: In vitro synergistic cytotoxicity and DNA-induced strand-breaks. Eur J Cancer 32A: 12191226.
  • 49
    Yasuda C, Kato M, Kuroda D, Ohyanagi H 1997 Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3′-azido-3′-deoxythymidine for the gastric cancer cell line MKN28 in vivo. Jpn J Cancer Res 88: 97102.
  • 50
    Wagner CR, Ballato G, Akanni AO, McIntee EJ, Larson RS, Chang S, Abul-Hajj YJ 1997 Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res 57: 23412345.
  • 51
    Wit FW, Sol CJ, Renwick N, Roos MT, Pals ST, van Leeuwen R, Goudsmit J, Reiss P 1998 Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS 12: 218219.
  • 52
    Tosi P, Gherlinzoni F, Visani G, Coronado O, Costigliola P, Mazzetti M, Gritti F, Chiodo F 1998 AZT plus methotrexate in HIV-related non-Hodgkin's lymphomas. Leuk Lymphoma 30: 175179.
  • 53
    Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, Nethersell AB, Conte PF 1996 Intravenous azidothymidine with fluorouracil and leucovorin: A phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 14: 729736.
  • 54
    Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM 1995 Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332: 17441748.
  • 55
    Peacock M 2002 Normalization of hypercalcemia with the calcimimetic AMG 073 in a patient with metastatic parathyroid cancer. J Bone Miner Res 17: S1: 381.
  • 56
    Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, McCary LC, Olson KA, Turner SA, Peacock M 2003 The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTX. J Bone Miner Res 18: S2: S171.
  • 57
    Rubin M, Sliney J, McCary LC, Silverberg SJ, Bilezikian JP 2003 Effective management of severe hypercalcemia with the calcimimetic cinacalcet HCl in patients with parathyroid carcinoma. J Bone Miner Res 18: S2: S392.